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Abstract
Introduction: Cell therapy is a rapidly growing area of research for the treatment of osteoarthritis (OA). This work
is aimed to investigate the efficacy of intra-articular adipose-derived stromal cell (ASC) injection in the healing
process on cartilage, synovial membrane and menisci in an experimental rabbit model.
Methods: The induction of OA was performed surgically through bilateral anterior cruciate ligament transection
(ACLT) to achieve eight weeks from ACLT a mild grade of OA. A total of 2 × 106 and 6 × 106 autologous ASCs
isolated from inguinal fat, expanded in vitro and suspended in 4% rabbit serum albumin (RSA) were delivered in
the hind limbs; 4% RSA was used as the control. Local bio-distribution of the cells was verified by injecting chloro-
methyl-benzamido-1,1’-dioctadecyl-3,3,3’3’-tetra-methyl-indo-carbocyanine per-chlorate (CM-Dil) labeled ASCs in the
hind limbs. Cartilage and synovial histological sections were scored by Laverty’s scoring system to assess the
severity of the pathology. Protein expression of some extracellular matrix molecules (collagen I and II), catabolic
(metalloproteinase-1 and -3) and inflammatory (tumor necrosis factor- a) markers were detected by
immunohistochemistry. Assessments were carried out at 16 and 24 weeks.
Results: Labeled-ASCs were detected unexpectedly in the synovial membrane and medial meniscus but not in
cartilage tissue at 3 and 20 days from ASC-treatment. Intra-articular ASC administration decreases OA progression
and exerts a healing contribution in the treated animals in comparison to OA and 4% RSA groups.
Conclusions: Our data reveal a healing capacity of ASCs in promoting cartilage and menisci repair and attenuating
inflammatory events in synovial membrane inhibiting OA progression. On the basis of the local bio-distribution
findings, the benefits obtained by ASC treatment could be due to a trophic mechanism of action by the release of
growth factors and cytokines.
Introduction
Osteoarthritis (OA) is one of the most common and wide-
spread rheumatic disease among adults with a significant
and negative impact on patient quality of life [1]. OA
affects the whole joint and is characterized by inflamma-
tion, bone remodeling and progressive destruction of the
articular cartilage components with following functional
disability [2]. In OA, the earliest changes in cartilaginous
tissue appear at the joint surface where mechanical forces
are greatest. Chondrocytes in OA cartilage, especially those
arranged in clonal clusters, exhibit cytokine and chemokine
receptors, increase production of matrix proteins and
matrix degrading enzymes leading to a modulation of
inflammatory and catabolic responses [3]. The altered
homeostasis of the extracellular matrix (ECM) macromole-
cules in cartilage tissue during OA leads to an increased
enzymatic activity of metalloproteinases (MMPs) [4] and
enhances the synthesis of pro-inflammatory molecules
[5,6] with following pain and joint instability. The currently
available treatments for OA are effective only on a short
term and there is a largely unmet medical need for durable
disease-modifying treatments [7]. Established therapies for
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OA include mainly preventive measures such as weight
control, exercise or pharmacologic approaches which
usually consist of analgesic therapy, including acetamino-
phen, salicylates and non-steroidal anti-inflammatory drugs
[8-10]. The feasibility of using mesenchymal stem cells
(MSC) from bone marrow or other tissue sites, based on
their capacity to influence and regulate different stages of
cartilage repair, is a challenge of considerable appeal to
clinicians. In particular, studies using animal models have
shown promising results following MSC therapy for the
treatment of musculoskeletal injuries [11]. In recent years,
several studies indicate that the therapeutic properties of
MSC are due not only to their capacity to differentiate but
also to their ability to release growth factors that regulate
the immune response in a paracrine manner [12,13]. Other
multipotent cell types have been found in different com-
partments, including adipose tissue, also known as adipose
derived stromal cells (ASCs) [14]. ASCs can easily be
obtained from liposuction waste in large quantities with lit-
tle donor site morbidity and are known to differentiate
along selected lineage pathways in response to specific
growth factors and environmental cues [15-18]. ASCs
represent valid candidates to promote cartilage and menisci
healing due to their ability to release biologically chondro-
genic active factors, such as transforming growth factor-b1
(TGF-b1) and bone morphogenetic protein 4 (BMP-4)
[19], anti-fibrotic and anti-apoptotic growth factors [20,21].
Moreover, some studies have provided insights into the
role of ASCs in suppressing immunoreactions as MSC
[22,23], suggesting their possible use in decreasing local
inflammation in several musculoskeletal diseases. Different
musculoskeletal treatments with ASCs have already been
reported with encouraging results for the regeneration of
cartilage and bone, even if the mechanism of action is not
clearly defined yet [24]. Up to date, functional data on the
role of ASCs in the care of osteoarthritis are, however, still
scarce [25-28]. The main aim of the current study was to
explore the efficacy of an intra-articular injection of ASCs
in preventing cartilaginous and menisci damages and
attenuating inflammation in synovial membrane following
the onset of OA in a rabbit model. In general, our findings
revealed a positive effect of ASCs in promoting cartilage
and menisci healing and contrasting inflammatory pro-
cesses in the synovial membrane.
Materials and methods
Rabbits
Adult male New Zealand rabbits (age: 12 months old,
body weight: 4 ± 0.5 Kg) were used. European and Italian
laws on animal experimentation were strictly followed
throughout the study. OA was induced surgically by
bilateral anterior cruciate ligament transection (ACLT)
[29,30]. Adipose tissue was harvested from the inguinal
zone for ASCs isolation. A total of 2 × 106 and 6 × 106
ASCs were re-suspended in 4% rabbit serum albumin
(RSA) (Sigma Aldrich, St. Louis, MO, USA) and adminis-
tered by an intra-articular injection into the hind limbs
after OA onset, eight weeks from ACLT. Four percent
RSA was used as a control group. A small number of ani-
mals were designed to monitor the fate of the cells at 3
and 20 days after ASC injection. Animals were sacrificed
respectively at short- (16 weeks) and long- (24 weeks)
term follow-ups from ASC administration to investigate
their effect on different compartments of the knee joint.
To this end, femoral condyles, meniscal and synovial tis-
sues were harvested. Table 1 shows the groups involved
in the experimental study.
Osteoarthritis model
For the ACLT procedure, a 2 cm skin and capsular inci-
sion was carried out and right and left ACLs were exposed
through a medial para-patellar cut. To achieve optimal
visualization of the ACL, the patellar bone was displayed
laterally and the knee was placed in full flexion. To avoid
spontaneous reattachment, the ACLT was associated to
the removal of a small fragment of tissue between the two
ligament stumps. The incision was sutured in a routine
fashion. After each operation, an antibiotic (Flumequine,
Sigma) and analgesic (Ketoprofene, Rhone-Poulenc-Rorer,
Sanofi Aventis, Strasbourg, France) therapy was adminis-
tered immediately after surgery and for two days there-
after. All surgical procedures were performed under
general anesthesia and sterile conditions.
ASC isolation and growth OK
Adipose tissue was harvested from the rabbit inguinal
zone and treated with 0.4 U/ml NB4 collagenase standard
grade (Serva Electrophoresis, GmbH, Heidelberg, Ger-
many) to isolate ASCs. The stromal vascular fraction
(SVF) containing ASCs was re-suspended in a-MEM
(Gibco, Carlsbad, CA, USA) supplemented with 1 U/ml
heparin (Sigma, St Louis, MO, USA), 2% platelet growth
factor enriched plasma (PGFEP) [31] and 0.05 g/ml peni-
cillin G (Gibco). Initially, ASCs were plated at a density of
4,000 cells/cm2 and cultured for a few days. Cells were
then harvested and seeded at a density of 2,000 cells/cm2
for the expansion. Viability was evaluated at SVF isolation
and expansion by the Trypan Blue dye exclusion method.
The selection of ASCs was carried out on the basis of their
ability to adhere to the plastic, to form colonies and to dif-
ferentiate into chondrogenic and osteogenic lineages
[15,32]. The number of population doublings (PD) was
calculated to verify rabbit ASCs growth during the culture
period.
ASCS administration
A total of 2 × 106 (cell density: 6 × 106 cells/ml) and 6 ×
106 (cell density: 18 × 106/ml) autologous ASCs at
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passage 1 in 4% RSA were prepared upon sterile condi-
tions in 1 ml syringes and delivered by an intra-articular
injection into the hind limbs at OA onset (eight weeks).
The needle was inserted into the knee joint posterior to
the lateral edge of the patella at the junction of the
femur and tibia to avoid damage to the articular carti-
lage. The sample was injected into the joint capsule and
the knee was flexed. The rabbit was held in this position
for a few minutes before recovery. Post-operative course
and long-term adverse events were monitored.
Local bio-distribution of ASCS
The fate of the ASCs was monitored by the local bio-
distribution evaluation at 3 and 20 days from ASC
administration. ASCs were labeled in vitro by 6 μM
chloro-methyl-benzamido-1,1’-dioctadecyl-3,3,3’3’-tetra-
methyl-indo-carbocyanine per-chlorate (CM-Dil) dye
(Molecular Probes, Carlsbad, CA, USA) [33] as indicated
by the manufacturer. A total of 6 × 106 labeled-ASCs
were injected in the hind limbs and un-labeled cells in
the contra-lateral ones, as the control. Cells were moni-
tored in vitro in parallel with the in vivo experiments (3
and 20 days) to evaluate ASCs’ viability, their doubling
time and their differentiation potential. Animals were
sacrificed and the different tissues (femoral condyle,
tibial plateau, synovial membrane, menisci, ligament and
articular capsule) were processed for histology by paraf-
fin embedding. Sections were analyzed by epi-fluores-
cent microscopy Eclipse 90i (Nikon, Melville, NY, USA)
by using 4’,6-diamidino-2-phenylindole (DAPI) and
TRITC filters to evaluate nuclear component and
labeled-ASCs, respectively.
Macroscopic imaging and histopathology
Macroscopic assessment of the knee joints from the ani-
mals that underwent ACLT was performed by India ink
staining (Higgings Waterproof Drawing Ink, Eberhard
Faber, Lewisburg, TN, USA) to assess cartilage lesions.
Macroscopic assessments were also performed in the
groups treated with 4% RSA and ASCs at 16 and 24 weeks
[34]. The histo-morphometric evaluations were performed
by image analysis Qwin v 2.4.4 software (Leica, Imaging
Systems, Cambridge, UK) on osteo-chondral specimens
embedded in metacrylate. Quantitative measurements of
cartilage thickness (CT) and fibrillation index (FI) in ASC-
treated groups and 4% RSA were carried out at both
experimental times. All the analyses were performed by
two blinded investigators according to the indications pro-
vided by Papaioannou and Pastoureau [35,36]. To perform
histological analysis, synovial membrane, menisci and
femoral condyles were placed in 10% neutral buffered for-
malin and osteo-chondral specimens were decalcified for
three weeks at room temperature (RT). Specimens were
paraffin embedded and thin sections (5 μm) were taken.
Hematoxylin/Eosin and Safranin-O/Fast Green (Sigma)
stainings were used to assess general morphology and pro-
teoglycans/collagen content in synovial, meniscal and car-
tilaginous tissues respectively. Semi-quantitative analyses
using appropriate scoring systems were used to evaluate
the cartilaginous and synovial tissues [37]. In particular,
the assessment of cartilage tissue was carried out with Lav-
erty’s scoring system which takes into account four para-
meters: Safranin-O/Fast Green staining, cartilage
structure, chondrocyte density and cluster formation. It
has a range from 0 to 24 where 0 translates to healthy car-
tilage while 24 to severe cartilage lesions. The assessment
of synovial tissue was performed with a semi-quantitative
scoring system that comprises the histological features of
synoviopathy in OA, including the synoviocytes (prolifera-
tion, hypertrophy), the inflammatory state and the synovial
stroma (hyperplasia, proliferation of blood vessels, prolif-
eration of fibroblasts, cartilage/bone detritus). It has a
range from 0 to 30 where 0 translates to a normal white,
semi-translucent smooth tissue and 30 indicates severe
proliferation, hypertrophy, inflammation and hyper-vascu-
larity. All the evaluations were performed by two blinded
researchers with an Eclipse 90i microscope (Nikon).
Immunohistochemistry
The analyses were carried out to evaluate type I and II col-
lagens, MMP-1, MMP-3 and TNF-a on cartilage, synovial
and meniscal specimens. Appropriate un-masking proce-
dures using specific treatments, including hyaluronidase
and pronase for collagens and citrate buffer solution for
Table 1 Description of the experimental design
Groups Number of animals Treatments Follow-up
Sham group 3 Sham operation 8 wks
OA group 9 ACLT 8, 16, 24 wks
4% RSA group 24 4% RSA 16 to 24 wks
2 × 106 ASC group 24 2 × 106 ASCs 16 to 24 wks
6 × 106 ASC group 24 6 × 106 ASCs 16 to 24 wks
Biodistribution group 9 labeled - ASCs 3, 7, 20 days
ACLT, anterior cruciate ligament transection; ASCs, adipose stem cells; OA, osteoarthritis; RSA, rabbit serum albumin; wks, weeks
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MMPs and TNF-a, followed by blocking steps were car-
ried out. Fixed samples were incubated at RT with mouse
monoclonal antibodies directed against type I collagen
(2 μg/ml) (Sigma), type II collagen (2 μg/ml) (Hybridoma
Bank, Department of Biological Sciences, University of
Iowa, Iowa City, IA, USA), MMP-1 (5 μg/ml) (Chemicon,
Temecula, CA, USA), MMP-3 (5 μg/ml) (Chemicon) and
TNF-a (2 μg/ml) (Santa Cruz Biotechnology, Inc., Santa
Cruz, CA, USA) respectively. Biotinylated secondary anti-
body and alkaline-labelled streptavidin (Biocare Medical,
Walnut Creek, CA, USA) were used. The reactions were
developed using Fast Red substrate (Biocare Medical).
Negative controls were performed either by omitting the
primary antibodies or using an isotype-matched control.
Six microscopic fields (100 × magnification) relative to the
anterior, central and posterior regions in cartilage tissue
were used to perform a semi-quantitative analysis of
immunohistochemistry. A semi-quantitative method that
assigns immunohistochemistry values as a percentage of
positive cells (collagen I, MMPs, TNF-a) or positive area
(extracellular matrix) (collagen II) was provided for a com-
plete assessment of protein expression, with maximum
scoring being 100%. The analysis was performed by two
blinded investigators using Red/Green/Blue (RGB) with
Software NIS-Elements and Eclipse 90i microscope
(Nikon).
Statistical analysis
Statistical analysis was carried out using the Statistical
Package for the Social Sciences (SPSS Inc., Chicago, IL,
USA) software version 15.0 (SPSS Inc.). Data for Laverty
scores, CT, FI, number of cluster formation and immu-
nohistochemical quantifications were expressed in terms
of 95% confidence intervals (CI) of the mean and/or
mean ± standard deviation (SD). The general linear
model (GLM) with Sidak correction for multiple com-
parisons was used to assess the influence of the kind of
treatment and follow-up on the different parameters
listed above. The Wilcoxon signed rank test was used
instead for paired comparisons in order to evaluate the
effects exerted by each group at the different experimen-
tal times.
Results
Development of mild grade of osteoarthritis
All the animals developed a mild grade of OA at eight
weeks after ACLT without any re-attachment of the liga-
ment. Macroscopic analysis gave evidence of varying
degrees of OA features in the OA group, with evident
black patches due to the uptake of India ink for cartilage
softening and fibrillation processes (Figure 1B) [38].
Histological findings revealed a series of OA changes,
including cartilage fibrillation and erosion, peri-articular
osteophytosis and moderate reduction in meta-chromatic
staining in the cartilage tissue (Figure 1D) [30,38]. As
concerns synovial tissue, thickening of the lining layer
and presence of inflammatory cells were observed by his-
tological analysis at eight weeks (Figure 1F). The investi-
gations on menisci revealed fibrillation processes in the
area of femoral attachment and an increased presence of
cell clusters by means of histological analysis (Figure 1H).
Local biodistribution of CM-Dil labeled ASCS into the OA
knee joint
The CM-Dil dye provided in vitro a uniform labeling of
the cells (90%) as assessed by fluorescence microscopy.
The staining did not affect the ASCs’ viability (95%), cell
doubling (2.09 PD at passage 1 and 1.7 PD at passage 3)
Figure 1 Degenerative changes in different articular compart-
ments in sham and OA groups at eight weeks. (A, B) India ink
staining of medial femoral condyle (MFC) of representative specimens.
Arrows, fibrillation processes (C, D) Safranin-O/Fast Green staining of
cartilage tissue of representative specimens. Arrows: Fibrillation and
delamination processes. (E, F) Hematoxylin/Eosin staining of synovial
membrane of representative specimens. Black arrows, Thickening of
lining layer; Red arrows, Inflammatory cells. (G, H) Safranin-O/Fast Green
staining of medial meniscus of representative specimens. Scale bars in
C, D = 1 mm; E-H = 100 μm.
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and differentiation potential into chondrogenic and
osteogenic lineages (Figure 2). Regardless of the bio-dis-
tribution in vivo, ASCs were clearly detected in the
synovial membrane and medial meniscus at 3 and 20
days (Figure 3). In particular, the presence of ASCs in
the lining layer of synovial membrane and a diffuse dis-
tribution along the thickness of fibro-cartilaginous and
vascular areas of the medial meniscus were noticed. No
cell engraftment was observed in the anterior cruciate
ligament, in the articular cartilage from the medial or
lateral femoral condyle and in the tibial plateau at any
of the experimental times evaluated (data not shown).
ASCS treatment prevents cartilage destruction
A glossy, white cartilage with no degenerative noticeable
macroscopic evidence was observed in the ASCS-treated
groups at both experimental times. Cartilage softening
and fibrillation were instead observed in the OA and 4%
RSA groups particularly in the medial regions (data not
shown). Histo-morphometric analyses provided further
information on the status of the structure of cartilage
tissue. Among the pathological changes recorded during
OA, an increase of FI was observed in OA group com-
pared to 4% RSA at both 16 and 24 weeks (P < 0.01). A sig-
nificant reduction of FI was noticed in both ASCs treated
groups at 16 weeks compared to 4% RSA at both experi-
mental times (P < 0,01), indicating a protective role of
ASCs in reducing fibrillation processes (Figure 4A). The
intra-articular delivery of 2 × 106 ASCs revealed an
increase of CT values respect the OA group and 4% RSA at
16 and 24 weeks (P < 0.01) (Figure 4B). Based on visual
assessment of the histological staining, there were
Figure 2 Chondrogenic and osteogenic differentiation of rabbit adipose stem cells (ASCs) in vitro. (A) Chondrogenic and osteogenic
differentiation of rabbit ASCs labeled with CM-Dil in vitro. (B) Growth curves of unlabeled and labeled ASCs (C).
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significant, overall effects of ASCs in the healing of cartila-
ginous tissue which displayed some hyaline features with a
smooth surface, a regular cellular arrangement and a high
proteoglycan content leading to a functional cartilage tissue
(Figure 5A, B). In particular, 2 × 106 ASC treatment
revealed a significant decrease of Laverty’s score at 16
weeks compared to the OA group (P < 0.01), which instead
gave evidence of a series of changes, including chondrocyte
Figure 4 Quantitative assessment of disease progression in the different groups. (A) Fibrillation index. (B) Cartilage thickness. Data are
reported in terms of mean ± SD. Statistical values of at least P < 0.01 were observed in all the comparisons.
Figure 3 Biodistribution of CM-Dil labeled ASCs. Detection of labeled-ASCs in synovial lining layer (A-D) and medial meniscus (E-H) of
representative specimens at 3 and 20 days from ASC administration under bright field (A, C, E, G) and epi-fluorescence (B, D, F, H). Blue staining
= nuclei; Red staining = CM-Dil labeled-ASCs. Scale bars = 500 μm.
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and proteoglycan loss, fibrillation and delamination pro-
cesses. A progression of the pathology, was also noticed in
the 4% RSA group at 16 and 24 weeks compared to OA
(P < 0.01). In general, ASC administration determined a
decrease of Laverty’s scores compared to 4% RSA (P <
0.01) at both experimental times.
ASCS treatment inhibits the thickening of lining layer in
synovium and reduces cluster formation in menisci
Synovial tissue after ACLT in OA group displayed at
eight weeks thickening of the lining layer and evidence of
infiltration by inflammatory cells. A progression of the
pathology was detected in the 4% RSA group at 16 and
24 weeks with an increase of Laverty’s score compared to
the OA group (P < 0.01). ASC administration (2 × 106
and 6 × 106) significantly decreased Laverty’s score at 16
and 24 weeks compared to the 4% RSA and OA groups
(P < 0.01). The protective effects exerted by the ASCs
were noticed overall in reducing the thickness of the
lining layer and the infiltration of inflammatory cells in
the sub-synovium. In particular, best results were noticed
in the 6 × 106 ASC-treated group at 16 weeks compared
to 24 weeks (P < 0.01) (Figure 6A, B). An histological
analysis on menisci was performed in order to determine
if ASC treatment had an effect on the meniscal compart-
ment. A significant increase of cell cluster was noticed in
the 4% RSA at 16 and 24 weeks compared to the OA
group (P < 0.01). The 2 × 106 and 6 × 106 ASC-treated
groups displayed a well organized tissue with a low num-
ber of cell clusters at 16 and 24 weeks compared to the
OA and 4% RSA groups at both experimental times (P <
0.01) (Figure 7A, B).
ASCS treatment reduces matrix degrading enzymes and
TNF-a in cartilage matrix
Since the degradation of cartilage matrix represents a key
event in the development of OA, we decided to test the
effect of ASC treatment on catabolic and inflammatory
Figure 5 Histological evaluation of medial femoral condyle in OA, 4% RSA and ASC-treated groups. (A) Safranin-O/Fast Green staining of
representative specimens. Black arrows, fibrillation and delamination processes. Red arrows, Erosion processes. Scale bars = 1,000 μm. (B) Laverty’s
score. Data are reported in terms of 95% confidence intervals. Statistical values of at least P < 0.01 were observed in all the comparisons.
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molecules involved in the OA onset. We first investigated
the typical hyaline marker, collagen type II, detecting a
decrease of this molecule in the 4% RSA at 24 weeks in
respect to the OA group (P < 0.01). ASC treatment gave
evidence of a chondro-protective effect, promoting the
expression of a great amount of type II collagen in the
cartilage tissue in respect to the OA and 4% RSA groups
(P < 0.01). In particular, high percentages of positive
areas in the 2 × 106 and 6 × 106 ASC-treated groups at
16 and 24 weeks were detected. A reduced expression of
collagen type II was noticed in 4% RSA, 2 × 106 and 6 ×
106 ASCs at 24 weeks compared to 16 weeks (P < 0.01)
(Figure 8A). Collagen type I, a fibro-cartilaginous marker,
reported an intense positivity at cellular level in the OA
group, particularly at the superficial level in cartilage
matrix. The 4% RSA group displayed an increased
expression of type I collagen particularly at 24 weeks
compared to the OA group (P < 0.01). A reduction of
collagen type I was detected in the ASC-treated groups at
short- and long-term follow-ups with respect to the 4%
RSA group (P < 0.01) (Figure 8B). A moderate expression
of MMP-1 was noticed in the OA group, particularly in
the superficial layer of cartilage. An increased expression
of this protein was observed in the 4% RSA group. By
contrast, ASC-treated groups showed a low expression
for MMP-1 compared to the OA group and 4% RSA
group at 16 and 24 weeks (P < 0.01) (Figure 9A). The OA
group displayed a moderate expression of TNF-a which
increased progressively in 4% RSA at 16 and 24 weeks
(P < 0.01). A reduction of TNF- a expression was
detected in both the ASC-treated groups at 16 weeks and
24 weeks with respect to the OA and 4% RSA groups
(P < 0.01) (Figure 9B).
ASCS treatment inhibits MMP-1 and TNF-a expression in
synovial membrane and menisci
The effect of ASC treatment on synovial membrane and
menisci was investigated by immunohistochemical ana-
lyses. The OA group displayed a mild positivity for
MMP-1, particularly in the lining layer of the synovial
membrane at eight weeks. A moderate expression of
MMP-1 was noticed in the 4% RSA group at short- and
Figure 6 Histological evaluation of synovial membrane in OA, 4% RSA and ASC-treated groups. (A) H/E staining of representative
specimens. Scale bars = 100 μm. (B) Laverty’s score. Data are reported in terms of the 95% confidence intervals. Statistical values of at least P <
0.01 were observed in all the comparisons.
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long-term follow-ups compared to the OA group (P <
0.01). ASC treatment reduced the expression for MMP-1
at both experimental times with respect to the 4% RSA
group (P < 0.01) (Figure 10A). As concerns TNF-a, the
OA group showed a mild positivity in the synovial lining
at eight weeks. An intense positivity for TNF-a was
observed in the 4% RSA at 16 and 24 weeks with respect
to the OA group (P < 0.01). ASC treatment decreased the
expression of TNF-a compared to the 4% RSA group at
16 and 24 weeks (P < 0.01) (Figure 10B). A series of
investigations was also focused on the status of medial
meniscus. The OA group showed a moderate positivity
for MMP-1 at the cellular level, particularly in the super-
ficial layer in the meniscal compartment at eight weeks.
An increase of MMP-1 expression was noticed in the 4%
RSA group at 24 weeks compared to the OA group (P <
0.01). By contrast, a reduction of MMP-1 was observed
in the ASC-treated groups at 16 weeks compared to the
OA group (P < 0.01). A slight increase in the expression
of this protein was detected in all the groups analyzed at
24 weeks compared to 16 weeks (P < 0.01) (Figure 11A).
The OA group showed a moderate positivity for TNF-a
at the cellular level at eight weeks. The 4% RSA group
displayed a strong expression of TNF-a at 16 and 24
weeks with respect to the OA group (P < 0.01). A slight
positivity was detectable in the ASC-treated groups at
both experimental times compared to the 4% RSA group
(P < 0.01) (Figure 11B).
Discussion
The employment of ASCs in regenerative medicine is a
rapidly growing area of research and some evidence of
therapeutic success using these cells for osteochondral
defect has been reported [39,40]. Recently, this cell ther-
apy is being used as a valid therapeutic tool also in the
treatment of OA. Beneficial effects of ASCs were
reported in the care of this pathology in some experi-
mental animal models [25-28]. However, most of these
Figure 7 Histological evaluation of menisci in OA, 4% RSA and ASC-treated groups. (A) Safranin-O/Fast Green staining of representative
specimens. Scale bars = 100 μm. (B) Numbers of cluster formation. All the data are reported as 95% confidence intervals. Statistical values of at
least P < 0.01 were observed in all the comparisons.
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Figure 8 Immunohistochemical analysis for collagen II and I in cartilage. Photomicrographs of representative specimens evaluated for type
II (A) and I (B) collagens in medial femoral condyle of OA, 4% RSA and ASC-treated groups. Data are reported as mean ± SD. Scale bars = 100
μm. Statistical values of at least P < 0.01 were observed in all the comparisons.
Figure 9 Immunohistochemical analysis for MMP-1 and TNF-a in cartilage. Photomicrographs of representative specimens evaluated for
MMP-1 (A) and TNF-a (B) in medial femoral condyle of OA, 4% RSA and ASC-treated groups. Data are reported as mean ± SD. Scale bars = 100
μm. Statistical values of at least P < 0.01 were observed in all the comparisons.
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studies were limited to macroscopic and histological
observations of articular cartilage after ASC treatment.
No information was provided on the effects of these cells
on catabolic and inflammatory processes which occur
during OA in synovial membrane and menisci. This
study, using a rabbit model of OA, was designed to deter-
mine the role of ASCs in the OA setting and their beha-
vior on inflammatory environment within the affected
articular joint. The ACLT model proposed is widely vali-
dated in investigating OA disease, because it determines
biomechanical and pathological changes similar to those
seen in humans [29]. It has been reported from our
group that eight weeks after ACLT, cartilage damages in
rabbits occur mainly in the medial femoral condyle,
showing a wide spectrum of OA changes, including fibril-
lation and delamination processes, altered cellular
arrangement and proteoglycan depletion [30]. The inves-
tigations performed on synovial membrane and menisci
revealed that the ACLT procedure at eight weeks leads to
a thickening of the lining layer in the synovial membrane
associated with the presence of some inflammatory ele-
ments and to an increase in cell cluster formation in
menisci. Direct intra-articular injection of cells is
technically the simplest approach to the use of cells for
OA therapy [13,41]. In the current study, an intra-articu-
lar injection of ASCs was delivered in the hind limbs of
the rabbits after OA induction. No animals showed swel-
ling at the injection sites, signs of distress, or hyperalgesia
after ASC administration. There were significant overall
effects of ASC treatment in the cartilaginous, synovial
and meniscal tissues at different levels. Our investigations
gave evidence of the beneficial effect for the 2 × 106 ASC
group, particularly at 16 weeks, showing a well-organized
tissue with a low Laverty’s score, an increased cartilage
thickness compared to the OA group. Both cell doses
provided good results showing a high expression of type
II collagen in the cartilage matrix at 16 and 24 weeks. A
positive contribution of the intra-articular delivery of
both ASC concentrations was also noticed in the menis-
cal compartment at both experimental times, leading to a
decrease of the number of cell clusters the fibro-cartilagi-
nous area. Cell treatment inhibits the progression of OA,
providing a reduction of the fibrillation index, Laverty’s
score and type I collagen in cartilage and favors the ana-
bolic processes addressed to the formation of a new tis-
sue. Moreover, ASC administration inhibits the
Figure 10 Immunohistochemical analysis for MMP-1 and TNF-a in synovial membrane. Photomicrographs of representative specimens
evaluated for MMP-1 (A) and TNF-a (B) in synovial membrane of OA, 4% RSA and ASC-treated groups. Data are reported as mean ± SD. Scale
bars = 100 μm. Statistical values of at least P < 0.01 were observed in all the comparisons.
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development of thickening of the lining layer in the syno-
vial membrane with major evidence at short-term follow-
up. Since the release of cartilage matrix proteins in the
articular environment contribute to cartilage damage
through the production of inflammatory cytokines, che-
mokines and MMPs [3], we decided to test the effects
exerted by ASCs. To this regard, clear benefits of ASC
treatment were observed with the reduction of the
inflammation in cartilage tissue in terms of a decreased
pattern of expression for TNF-a at both experimental
times [42]. In close correlation with the reduction of
TNF-a, a decreased level of MMP-1 in cartilage tissue,
responsible of proteoglycan degradation, was noticed in
ASC-treated groups at 16 and 24 weeks [42,43]. A time-
dependent effect of ASC treatment was noticed for
MMPs and TNF-a expression, particularly in the 2 × 106
ASC group providing the best results at short-term
follow-up. Cell treatment inhibits the progression of OA,
leading to a reduction of TNF-a and MMPs in menisci
and synovial membrane at both experimental times. In
general, the 4% RSA group displayed OA progression in
the different compartments as indicated by an increased
expression of catabolic and inflammatory markers. Both
ASC doses gave evidence of the healing potential in
cartilage, synovial membrane and menisci, even if the
lowest cell concentration is more effective on cartilage
repair at 16 weeks. The underlying mechanisms responsi-
ble of the best effects of 2 × 106 ASCs in cartilage are not
fully understood. It could be related to the release of
cytokines and other growth factors by ASCs that at low
and high concentrations can determine contrasting biolo-
gical effects on the immune system and/or on catabolic
and inflammatory events. A time-dependent effect by
ASCs was observed in the analysis performed particularly
on cartilage tissue, detecting the best findings at short-
term follow-up. These findings could be justified by the
lack of repair of the anterior cruciate ligament, which
could slow and/or inhibit some signaling pathways
involved in the repair processes. The investigations per-
formed on the local bio-distribution of ASCs by using a
fluorescent tracking dye (CM-Dil) open some prospec-
tives in the understanding of the mechanism of action by
ASCs. The key advantage of CM-Dil and its derivatives is to
represent a nontoxic fluorescent tracking system ready in a
few hours, able to label ASCs without altering their multi-
potential nature as observed by in vitro differentiation pro-
tocols and avoiding genetic manipulation of the cells [33].
Nevertheless, this system shows some disadvantages such as
Figure 11 Immunohistochemical analysis for MMP-1 and TNF-a in menisci. Photomicrographs of representative specimens evaluated for
MMP-1 (A) and TNF-a (B) in medial menisci of OA, 4% RSA and ASC-treated groups. Data are reported as mean ± SD. Scale bars = 100 μm.
Statistical values of at least P < 0.01 were observed in all the comparisons.
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the loss of fluorescence signal over time during cell replica-
tion rendering difficult the cell tracking at long term follow-
up, the transfer of the fluorescent dye to other cells.
After having injected labeled cells, no engraftment was
noticed in the anterior cruciate ligament and in the carti-
laginous tissue from the tibial plateau and femoral con-
dyles. The homing of these cells was unexpectedly
detected in the synovial and medial meniscus, probably
due to the expression of specific receptors or ligands able
to facilitate trafficking, adhesion and infiltration of ASCs
to these sites and/or to the presence of a vascular fraction
which could promote ASC migration. The distribution of
ASCs in the lining layer of synovial tissue could also be
due to the release of chemokines by macrophages located
within the lining layer [44]. Different hypotheses could
be provided to explain the chondro-protective and heal-
ing effects exerted by ASCs. Cell administration could
contribute to enhance anabolic signaling pathways and
inhibit catabolic ones. These processes could be reason-
ably induced by growth factors and cytokines released by
ASCs rather than their differentiation potential since bio-
distribution data showed the localization of ASCs in the
synovial and meniscal tissues.
Another mechanism exerted by ASCs could be due to
the inhibition of the release of catabolic and inflamma-
tory molecules by macrophages in synovium or chondro-
cytes in cartilage. Experimental evidence supports this
hypothesis, reporting a decrease of the catabolic and
inflammatory molecules predominantly in cartilage.
Other possibilities could be projected on the regulation
of the immune system by ASCs as already observed for
MSC [37,45]. Several authors have shown how the
inflammatory environment is an important parameter to
consider, since it would seem to influence the behavior of
ASCs by enhancing their immunosuppressive potential
[46-49]. This last consideration provides more attention
on the pattern of molecules secreted by ASCs, which
could have important implications in the resolution of
inflammatory diseases. Further analysis of the molecules
secreted by ASCs could be useful to identify key elements
involved in repair processes. In conclusion, the findings
of this study demonstrate that an intra-articular injection
of ASCs exerts a chondro-protective role promoting a
series of anabolic processes in order to allow the mainte-
nance of a good collagen and proteoglycan network, and
at the same time inhibiting catabolic events responsible
for degenerative events in cartilage, synovial and meniscal
tissues. ASC therapy could, therefore, represent a novel
therapeutic tool for the treatment of osteoarthritis.
Conclusions
The current study was the first to focus on the effect of
ASCs in the OA setting and their behavior on the
inflammatory environment within the cartilaginous,
synovial and meniscal tissues in a rabbit model of
osteoarthritis. Our data demonstrated a healing effect by
ASCs on cartilage and menisci and an inhibition of OA
progression in synovial membrane. Biodistribution of
ASCs in medial meniscus and synovium provides some
suggestions on their possible role suggesting a paracrine
mechanism of action.
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